Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate) (1)

Analgesic (2) · Androgen / Anabolic Steroid (1) · Dissociative (1) · Opioid (2) · Prodrug (1) · Research material (1)

Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT. (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · NMDA antagonist; fluorinated ketamine analogue (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d. (1)

None (2) · Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · Formulation-dependent (1)

None (2) · buccal (1) · IM (1) · nasal (1) · oral (undecanoate only) (1) · PO (only formulation marketed in the US). (1) · Topical (gel/patch) (1)

None (2) · 30–60 min (PO) (1) · Hours (transdermal); days (IM esters) (1)

None (2) · 4–6 hours (1) · Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM) (1)

None (2) · 2.5–3 hours (1) · Highly variable by formulation; native T is hours (1)

None (2) · Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category X, contraindicated; teratogenic (virilization of female fetus) (1)

None (2) · Schedule III (DEA, US) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)